Losartan in Cushing's syndrome - PubMed (original) (raw)
Clinical Trial
Losartan in Cushing's syndrome
S Zacharieva et al. Methods Find Exp Clin Pharmacol. 1998 Mar.
Free article
Abstract
Eleven patients with Cushing's syndrome were included in the study. They maintained their usual sodium intake and received a single oral dose of 50 mg of the angiotensin II antagonist receptor losartan for 3 days. Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity. Both systolic and diastolic blood pressure decreased independently of baseline level of active renin. The relationship between kallikrein and renin-angiotensin system are discussed.
Similar articles
- Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension.
Zacharieva S, Torbova S, Orbetzova M, Vergilova J, Nachev E, Wippermann M, Baurenski L, Angelova-Gateva P, Tzingilev D. Zacharieva S, et al. Methods Find Exp Clin Pharmacol. 1998 Jun;20(5):433-8. doi: 10.1358/mf.1998.20.5.485705. Methods Find Exp Clin Pharmacol. 1998. PMID: 9701782 - Contribution of the renin-angiotensin and kallikrein-kinin systems to short-term variability of blood pressure in two-kidney, one-clip hypertensive rats.
Ponchon P, Elghozi JL. Ponchon P, et al. Eur J Pharmacol. 1996 Feb 15;297(1-2):61-70. doi: 10.1016/0014-2999(95)00721-0. Eur J Pharmacol. 1996. PMID: 8851167 - Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Zacharieva S, Atanassova I, Natchev E, Orbetzova M, Tzingilev D. Zacharieva S, et al. Methods Find Exp Clin Pharmacol. 2001 Apr;23(3):153-6. doi: 10.1358/mf.2001.23.3.627950. Methods Find Exp Clin Pharmacol. 2001. PMID: 11523316 Clinical Trial. - Hypertension in Cushing's syndrome.
Magiakou MA, Smyrnaki P, Chrousos GP. Magiakou MA, et al. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):467-82. doi: 10.1016/j.beem.2006.07.006. Best Pract Res Clin Endocrinol Metab. 2006. PMID: 16980206 Review. - The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist.
Duncia JV, Carini DJ, Chiu AT, Johnson AL, Price WA, Wong PC, Wexler RR, Timmermans PB. Duncia JV, et al. Med Res Rev. 1992 Mar;12(2):149-91. doi: 10.1002/med.2610120203. Med Res Rev. 1992. PMID: 1619965 Review. No abstract available.
Cited by
- Cushing's syndrome: all variants, detection, and treatment.
Sharma ST, Nieman LK. Sharma ST, et al. Endocrinol Metab Clin North Am. 2011 Jun;40(2):379-91, viii-ix. doi: 10.1016/j.ecl.2011.01.006. Endocrinol Metab Clin North Am. 2011. PMID: 21565673 Free PMC article. - Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.
Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro M. Arnaldi G, et al. J Endocrinol Invest. 2012 Apr;35(4):434-48. doi: 10.1007/BF03345431. J Endocrinol Invest. 2012. PMID: 22652826 Review. - Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.
Fardet L, Fève B. Fardet L, et al. Drugs. 2014 Oct;74(15):1731-45. doi: 10.1007/s40265-014-0282-9. Drugs. 2014. PMID: 25204470 Review. - Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment.
García San José P, Arenas Bermejo C, Alonso-Miguel D, Clares Moral I, Cuesta-Alvaro P, Pérez Alenza MD. García San José P, et al. J Vet Intern Med. 2021 Jan;35(1):130-141. doi: 10.1111/jvim.15978. Epub 2020 Dec 4. J Vet Intern Med. 2021. PMID: 33274787 Free PMC article. - Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management.
Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI. Sacerdote A, et al. Curr Hypertens Rep. 2005 Jun;7(3):212-8. doi: 10.1007/s11906-005-0013-4. Curr Hypertens Rep. 2005. PMID: 15913497 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical